MediLink Therapeutics (“MediLink”) today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumor types. Under the terms of the agreement, MediLink will grant Roche […]
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported positive topline results from its randomized, head-to-head Phase 1b JADE clinical study comparing IBI324 (Ollin
Calgary, Alberta–(Newsfile Corp. – January 8, 2026) – Olympia Financial Group Inc. (TSX: OLY) announces that its Board of Directors has declared a monthly cash dividend on its common shares of $0.60 per common share. The dividend will be payable on January 30, 2026, to shareholders on record as at January 21, 2026. Olympia Financial
PureField Ingredients today announced the appointment of Luciano Salvatierra as Chief Financial Officer, strengthening the company’s leadership team as it continues to scale its food ingredients platform and advance its low-carbon biofuels and carbon sequestration strategy. Salvatierra brings more than 23 years of leadership experience across agrifood and renewable fuels value chains, most recently in
Enbridge Inc. (TSX: ENB) (NYSE: ENB) (Enbridge or the Company) will host a conference call and webcast on February 13, 2026, at 7 a.m. MT (9 a.m. ET) to provide a business update and review 2025 fourth quarter results. The conference call format will include prepared remarks from the executive team, followed by a question-and-answer
(AUST:MSB.AX),(NASDAQ:MESO), NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$35.1 million on Ryoncil(R) (remestemcel-L-rknd) sales for the quarter ended December 31, 2025.1 This represents a 60% increase on the prior quarter ended September 30, 2025. Ryoncil(R) is
Ryoncil(R) Sales Increase 60% in December Quarter to US$35.1M Strong Balance Sheet Reflects Revenue Growth and New $125M Five-Year Facility GlobeNewswire January 08, 2026 NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$35.1 million on Ryoncil(R) (remestemcel-L-rknd)
NEW YORK CITY, NY / ACCESS Newswire / January 8, 2026 / WHY: New York, N.Y., January 8, 2026. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Klarna Group plc (NYSE:KLAR) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with
Nuvo, a leader in remote fetal-maternal monitoring, together with Celebrate Life Around the Word Foundation (CLAW), a global non-governmental 501(c)(3) non-profit organization dedicated to improving health in underserved settings, announce the launch of the Nuvo-CLAW Fetal-Maternal Global Health Access Program, a multi-year initiative to expand access to high-quality pregnancy monitoring and maternal-fetal care worldwide. Nuvo,
Washington, D.C.–(Newsfile Corp. – January 8, 2026) – The Securities and Exchange Commission’s Office of the Advocate for Small Business Capital Formation today published and delivered to Congress its 2025 staff report that serves as a comprehensive and data-rich resource on capital-raising dynamics nationwide. The report presents data across three company lifecycle stages to provide